Real-world data on the use of nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) are limited. A cross-sectional study within a retrospective multinational clinical consortium (2000–2021 REAL-B consortium) was examined to determine rates of CHB evaluation and treatment. Of 12,566 treatment-naive adults with CHB from 25 centres across 9 countries (mean age 47.1 years, 41.7% female patients, 96.1% Asian ethnicity, 49.6% Western region), 73.3% received adequate evaluation. Of those evaluated, 32.6% were eligible for treatment according to international guidelines, but only 83.3% of whom initiated antiviral treatment. After adjusting for multivariables, treatment rates were found to be lower in female patients than in male patients (~50% less likely to initiate NAs), and also in Asian Americans (versus Asian patients from East Asia or non-Asian patients; ~40–50% less likely to undergo evaluation and initiate NAs).

关于使用核苷（酸）类似物（NA）治疗慢性乙型肝炎（CHB）的真实世界数据有限。对回顾性跨国临床联盟（2000-2021 REAL-B 联盟）进行的一项横断面研究进行了检查，以确定 CHB 评估和治疗率。来自 9 个国家 25 个中心的 12,566 名初治慢性乙型肝炎成人患者（平均年龄 47.1 岁，41.7% 女性患者，96.1% 亚洲人，49.6% 西部地区）中，73.3% 的患者接受了充分的评估。在接受评估的人中，32.6% 的人符合国际指南的治疗条件，但其中只有 83.3% 的人开始了抗病毒治疗。调整多变量后，发现女性患者的治疗率低于男性患者（开始 NA 的可能性低约 50%），亚裔美国人的治疗率也低于男性患者（与来自东亚的亚洲患者或非亚洲患者相比；约 40） – 接受评估和启动 NA 的可能性降低 50%）。